# Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

> **NCT02464657** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 44 (actual)

## Conditions studied

- Leukemia
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Solu-medrol
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02464657
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2020-05-07
- **Final completion:** 2020-05-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464657, "Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02464657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*